Host-guest system of etodolac in native and modified β-cyclodextrins: Preparation and physicochemical characterization

Journal of Inclusion Phenomena and Macrocyclic Chemistry

Volumn 77, Issue 1-4, 2013, Pages 121-134

  Ammar, H O ^d   Ghorab, M ^b   Mostafa, D M ^a   Makram, T S ^c   Ali, R M ^c  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c 6 October Governorate   (Egypt)

^d FUTURE UNIVERSITY IN EGYPT   (Egypt)

Author keywords

Cyclodextrin; Complex; Etodolac; HP cyclodextrin; Me cyclodextrin; Stoichiometry

Indexed keywords

EID: 84888366727     PISSN: 09230750     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10847-012-0223-8     Document Type: Article

References (77)

1. Kean, W.F., Buchanan, W.W.: The use of NSAIDs in rheumatic disorders: a global perspective. Inflammopharmacology 13, 343-370 (2005)
2. McGeer, P.L., McGeer, E.G.: NSAIDs and Alzheimer disease: epidemiological animal model and clinical studies. Neurobiol. Aging 28, 639-647 (2007)
3. Voutsadakis, I.A.J.: Pathogenesis of colorectal carcinomaand therapeutic implications: the roles of ubiquitin-proteasome system and COX-2. Cell Mol. Med. 11, 252-285 (2007)
4. Demerson, C.A., Humber, L.G., Abraham, N.A., Schilling, G., Martel, R.R., Pace-Asciak, C., et al.: Resolution of etodolac and anti-inflammatory and prostaglandin synthetase inhibiting properties of the enantiomers. J. Med. Chem. 26, 1778-1780 (1983)
5. Aungst, B.J.: Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism. J. Pharm. Sci. 82, 979-987 (1993)
6. Rainsford, K.D.: Inhibitors of eicosanoids. In: Curtis, P. (ed.) The Eicosanoids, pp. 189-210. Wiley, Chichester (2004)
7. Vane, J.R., Botting, R.M.: New insights into the mode of action of anti-inflammatory drugs. Inflamm. Res. 44, 1-10 (1995)
8. Vane, J.R., Botting, R.M.: Therapeutic Roles of Selective COX-2 Inhibitors. William Harvey Press, London (2001)
9. Tarnawski, A.S., Jones, M.K.: Inhibition of angiogenesis by NSAIDs: molecular mechanisms and clinical implications. J. Mol. Med. 81(10), 627-636 (2003)
10. Rainsford, K.D.: Salicylates in the treatment of acute pain. In: Rainsford, K.D. (ed.) Aspirin and Related Drugs, pp. 587-618. CRC Press, Boca Raton (2004)
11. Rainsford, K.D.: Introduction - the coxib controversies. Inflammopharmacology 13, 331-341 (2005)
12. Milic-Askrabic, J., Rajic, D.S., Tasic, L., Djuric, S., Kasa, P., Pintye-Hodi, K.: Etodolac and solid dispersion with b-cyclodextrin. Drug Dev. Ind. Pharm. 23, 1123-1129 (1997)
13. Bellamy, N.: Etodolac in the management of pain: a clinical review of a multipurpose analgesic. Inflammopharmacology 5, 139-152 (1997)
14. Verburg, K.M., Maziasz, T.J., Weiner, E., Loose, L., Geis, G.S., Isakson, P.C.: COX-2-specific inhibitors: definition of a new therapeutic concept. Am. J. Ther. 8, 49-64 (2001)
15. Becket, G., Schep, L.J., Tan, M.Y.: Improvement of the in vitro dissolution of praziquantel by complexation with alpha-, beta- and gamma-cyclodextrins. Int. J. Pharm. 179(1), 65-71 (1999)
16. Szente, L., Szejtli, J.: Highly soluble cyclodextrin derivatives: chemistry, property, and trends in development. Adv. Drug Deliv. Rev. 36, 17-28 (1999)
17. Lindberg, B., Lindberg, J.: Synthesis of some 2-O-(2-hydroxyalkyl) and 2-O-(2, 3-dihydroxyalkyl) derivatives of cyclomaltoheptaose. Carbohydr. Res. 222, 113-119 (1991)
18. Jambhekar, S., Casella, R., Maher, T.: The physicochemical characteristics and bioavailability of indomethacin from β-cyclodextrin, hydroxyethyl-β-cyclodextrin, and hydroxypropyl-β-cyclodextrin complexes. Int. J. Pharm. 270, 149-166 (2004)
19. Manosroi, J., Apriyani, M.G., Foe, K., Manosroi, A.: Enhancement of the release of azelaic acid through the synthetic membranes by inclusion complex formation with hydroxypropyl-β-cyclodextrin. Int. J. Pharm. 293, 235-240 (2005)
20. Wenz, G., Hofler, T.: Synthesis of highly water-soluble cyclodextrin sulfonates by addition of hydrogen sulfite to cyclodextrin allyl ethers. Carbohydr. Res. 322, 153-165 (1999)
21. Shuang, S., Choi, M.M.F.: Retention behaviour and fluorimetric detection of procaine hydrochloride using carboxymethyl-β-cyclodextrin as an additive in reversed-phase liquid chromatography. J. Chromatogr. A 919, 321-329 (2001)
22. Sabah, S., Scriba, G.K.E.: pH-dependent reversal of the chiral recognition of tripeptide enantiomers by carboxymethyl-β-cyclodextrin. J. Chromatogr. A 833, 261-266 (1999)
23. Loftsson, T., Brewster, M.E.: Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 85(10), 1018 (1996)
24. Higuchi, T., Connors, K.: Phase solubility techniques. Adv. Anal. Chem. Instrum. 4, 117 (1965)
25. Challa, R., Ahuja, A., Ali, J., Khar, R.K.: Cyclodextrins in drug delivery: an updated review. AAPS Pharm. Sci. Technol. 6(2), E329-E357 (2005)
26. Londhe, V., Nagarsenker, M.: Comparison between hydroxypropyl-β- cyclodextrin and polyvinyl pyrrolidine as carriers for carbamazepine solid dispersions. Indian J. Pharm. Sci. 61, 237-240 (1999)
27. Loftsson, T., Stefánsson, E.: Effect of cyclodextrins on topical drug delivery to the eye. Drug Dev. Ind. Pharm. 23, 473-481 (1997)
28. Van Dorne, H.: Interaction between cyclodextrins and ophthalmic drugs. Eur. J. Pharm. Biopharm. 39, 133-139 (1993)
29. Orfanou, F., Michaleas, S., Benaki, D., Galanopoulou, O., Voulgari, A., Antoniadou-Vyza, E.: Photostabilization of oxolinic acid in hydroxypropyl β- cyclodextrins; implications for the effect of molecular self-assembly phenomena. J. Incl. Phenom. Macrocycl. Chem. 64, 289-297 (2009)
30. Cristina, T., Iulia, M., Mihaela H.: The determination of the stoichiometry of cyclodextrin inclusion complexes by spectral methods: possibilities and limitations. In: Stoichiometry and Research - The Importance of Quantity in Biomedicine, pp. 47-76. InTech, Romania (2012). doi: 10.5772/34287
31. Pal, R.C., Roxana-Diana, P., santa, S., Irina, K., Gheorghe, T., Aurora, M., Ossi, H., Tomoaia-Cotisel, M.: Inclusion complex of β-cyclodextrin and quercetin. Thermodyn Approach. Rev. Chim. 62(10), 992-997 (2011)
32. Filipović-Grčić, J., Voinovich, D., Moneghini, M., Bećirević-Laćan, M., Magarotto, L., Jalšenjak, I.: Chitosan microspheres with hydrocortisone and hydrocortisone-hydroxypropyl- β-cyclodextrin inclusion complex. Eur. Pharm. Sci. 9, 373-379 (2000)
33. Loftsson, T., Hreindóttir, D., Másson, M.: Evaluation of cyclodextrins solubilization of drugs. Int. J. Pharm. 302, 18-28 (2005)
34. Loftsson, T., Hreindóttir, D., Másson, M.: The complexation efficiency. J. Incl. Phenom. Macrocycl. Chem. 57, 545-552 (2007)
35. Job, P.: Formation and stability of inorganic complexes in solution. Ann. Chim. 9, 113-203 (1928)
36. Soares, L.A., Leal, A.F.V.B., Fraceto, L.F., Maia, E.R., Resck, I.S., Kato, M.J., Gil, E.S., Sousa, A.R., Cunha, L.C., Rezende, K.R.: Host-guest system of 4-nerolidylcatechol in 2-hydroxypropyl β- cyclodextrin: preparation, characterization and molecular modeling. J. Incl. Phenom. Macrocycl. Chem. 64, 23-35 (2009)
37. Jadhav, G.S., Vavia, P.R., Nandedkar, T.D.: Danazol-β cyclodextrin binary system: a potential application in emergency contraception by the oral route. AAPS Pharm. Sci. Technol. 8(2), Article 35 (2007)
38. Uekema, K., Horiuchi, Y., Kikuchi, M., Hirayama, F., Ijitsu, T., Ueno, M.: Enhanced dissolution and oral bioavailability of R-tocopheryl esters by dimethyl-β-cyclodextrin complexation. J. Incl. Phenom. 6, 167-174 (1988)
39. Santos, J.V., de Carvalho, L.A.E.B., Pina, M.E.T.: The influence of the compression force on zidovudine release from matrix tablets. AAPS Pharm. Sci. Technol. 11(3), 1442-1448 (2010)
40. Sinha, V.R., Chadha, A.R., Goel, H.: Enhancing the dissolution of hydrophobic guests using solid state inclusion complexation: characterization and in vitro evaluation. J. Incl. Phenom. Macrocycl. Chem. 66, 381-392 (2010)
41. Barakat, N.S.: Etodolac-liquid-filled dispersion into hard gelatin capsules: an approach to improve dissolution and stability of etodolac formulation. Lett. Drug Des. Discov. 32, 865-876 (2009)
42. Wang, Y., Jiang, Z.T., Li, R.: Complexation and molecular microcapsules of Litsea cubeba essential oil with β-cyclodextrin and its derivatives. Eur. Food Res. Technol. 228, 865-873 (2009)
43. Ranjha, N.M., Khan, H., Naseem, S.: Encapsulation and characterization of controlled release flurbiprofen loaded microspheres using beeswax as an encapsulating agent. J. Mater. Sci. 21, 1621-1630 (2010)
44. Terekhova, I.V., Obukhova, N.A.: Study on inclusion complex formation of m-aminobenzoic acid with native and substituted β-cyclodextrins. J. Solut. Chem. 36, 1167-1176 (2007)
45. Spulber, M., Pinteala, M., Fifere, A., Moldoveanu, C., Mangalagiu, I., Harabagiu, V., Simionescu, B.C.: Water soluble complexes of methyl β-cyclodextrin and sulconazole nitrate. J. Incl. Phenom. Macrocycl. Chem. 62, 135-142 (2008)
46. 1H-nuclear magnetic resonance and phase solubility studies of the stoichiometries in 2,4-D: α- and β-cyclodextrins inclusion complexes. J. Incl. Phenom. Macrocycl. Chem. 37, 171-178 (2000)
47. Loftsson, T., Magnúsdóttir, A., Másson, M., Sigurjónsdóttir, J.F.: Self-association and cyclodextrin solubilization of drugs. J. Pharm. Sci. 91, 2307-2316 (2002)
48. Loftsson, T., Másson, M., Brewster, M.E.: Self-association of cyclodextrins and cyclodextrin complexes. J. Pharm. Sci. 93, 1091-1099 (2004)
49. Witte, F., Hoffmann, H.: Aggregation behavior of hydrophobically modified β-cyclodextrins in aqueous solution. J. Incl. Phenom. Mol. Recognit. Chem. 25, 25-28 (1996)
50. Auzely-Velty, R., Djedaieni-Pilard, F., Desert, S., Perly, B., Zemb, T.: Micellization of hydrophobically modified cyclodextrins. 1. Micellar structure. Langmuir 16, 3727-3734 (2000)
51. Munoz-Botella, S., Martin, M., Lerner, D.A.: Analytical applications of retinoid cyclodextrin inclusion complexes. J. Pharm. Biomed. Anal. 14, 909-915 (1996)
52. Ozkan, Y., Atay, T., Dikmen, N., Işimer, A., Aboul-Enein, H.Y.: Improvement of water solubility and in vitro dissolution rate of gliclazide by complexation with β-cyclodextrin. Pharm. Acta Helv. 74, 365-370 (2000)
53. Schalley, C.: Analytical Methods in Supramolecular Chemistry. Wiley-VCH, Weinheim (2007)
54. Imonigie, J.A., Macartney, D.H.: Effects of cyclodextrin inclusion on the kinetics on the outer-sphere oxidation of 4-tertbutylcatechol by transition metal complexes in acidic aqueous media. Inorg. Chem. 32(6), 1007-1012 (1993)
55. Tønnesen, H.H., Másson, M., Loftsson, T.: Studies of curcuminand curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability. Int. J. Pharm. 244(1-2), 127-135 (2002)
56. Blanco, J., Vila-Jato, J.L., Otero, F., Anguiano, S.: Influence of method of preparation on inclusion complexes of naproxen with different cyclodextrins. Drug Dev. Ind. Pharm. 17, 943Y-957Y (1991)
57. Brewster, M.E., Loftsson, T.: Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Deliv. Rev. 59, 645-666 (2007)
58. Stella, V.J., Rajewski, R.A.: Cyclodextrins: their future in drug formulation and delivery. Pharm. Res. 14, 556-567 (1997)
59. Connors, K.A.: Population characteristics of cyclodextrin complex stabilities in aqueous solution. J. Pharm. Sci. 84, 843-848 (1995)
60. Connors, K.A.: The stability of cyclodextrin complexes in solution. Chem. Rev. 97, 1325-1357 (1997)
61. Rao, V.M., Stella, V.J.: When can cyclodextrins be considered for solubilizing purposes. J. Pharm. Sci. 92, 927-932 (2003)
62. Marques, H.M.C., Hadgraft, J., Kellaway, I.W.: Studies of cyclodextrin inclusion complexes. I. The salbutamol-cyclodextrin complex as studied by phase solubility and DSC. Int. J. Pharm. 63, 259-266 (1990)
63. Chaves, I.S., Rodrigues, S.G., Melo, N.F.S., de Jesus, M.B., Fraceto, L.F., de Paula, E., Pinto, L.M.A.: Alternativas para o tratamento da esquistossomose: caracterizacÂ̧ão físico-química docomplexo de inclusão entre praziquantel e hidroxipropil-β- ciclodextrina. Lat. Am. J. Pharm. 29, 1067-1074 (2010)
64. Rodrigues, S.G., Souza, I.C., Melo, N.F.S., Jesus, M.B., Fraceto, L.F., Fernandes, S.A., Paula, E., Freitas, M.P., Pinto, L.M.A.: Computational analysis and physico-chemical characterization of an inclusion compound between praziquantel and methyl β-cyclodextrin for use as an alternative in the treatment of schistosomiasis. J. Incl. Phenom. Macrocycl. Chem. 70, 19-28 (2011)
65. Bettinetti, G., Gazzaniga, A., Mura, P., Giordano, F., Setti, M.: Thermal behavior and dissolution properties of naproxen in combinations with chemically modified beta-cyclodextrins. Drug Dev. Ind. Pharm. 18, 39-53 (1992)
66. Fielding, L.: Determination of association constants (Ka) from solution NMR data. Tetrahedron 56, 6151 (2000)
67. Magnusdottir, A., Másson, M., Loftsson, T.: Self association and cyclodextrin solubilization of NSAIDs. J. Incl. Phenom. Macrocycl. Chem. 44, 213-218 (2002)
68. Veiga, M.D., Diaz, P.J., Ahsan, F.: Interactions of griseofulvin with cyclodextrins in solid binary systems. J. Pharm. Sci. 55, 891-900 (1998)
69. Kacsó, I., Borodi, G., Farcas, S.I., Hernanz, A., Bratu, I.: Host-guest system of vitamin B10 in β-cyclodextrin: characterization of the interaction in solution and in solid state. J. Incl. Phenom. Macrocycl. Chem. 68, 175-182 (2010)
70. Venvenkatesh, D.N., Karthick, S., Umesh, M., Valliappan, R.M., Vivek, G., Samanta, M.K., Elango, K.: Studies on the preparation and characterization of β-cyclodextrin-aceclofenac inclusion complexes. Malays. J. Pharm. Sci. 7(2), 153-168 (2009)
71. Esclusa-Diaz, M.T., Gayo-Otero, M., Perez-Marcos, M.B., Vila-Jato, J.L., Labandeira, J.J.T.: Preparation and evaluation of ketoconazole-beta-cyclodextrin multicomponent complexes. Int. J. Pharm. 142, 183-187 (1996)
72. Mura, P., Adragna, E., Rabasco, A.M., Moyano, J.R., Perez-Martinez, J.I., Arias, M.J., Gines, J.M.: Effects of the host cavity size and the preparation method on the physicochemical properties of ibuproxam-cyclodextrin systems. Drug Dev. Ind. Pharm. 25, 279-287 (1999)
73. Sinha, V.R., Chadha, R.A., Goel, H.: Inter-molecular physiochemical characterization for etodolac-hydroxypropyl-β-cyclodextrin polymeric systems in solid and liquid state. Cent. Eur. J. Chem. 8(4), 953-962 (2010)
74. Sinha, V.R., Anitha, R., Ghosh, S., Nanda, A., Kumria, R.: Complexation of celecoxib with β-cyclodextrin: characterization of the interaction in solution and in solid state. J. Pharm. Sci. 94, 676-687 (2005)
75. Ryan, J.A.: Compressed pellet X-ray diffraction monitoring for optimization of crystallinity in lyophilized solids: imipenem:cilastatin sodium case. J. Pharm. Sci. 75, 805-807 (1986)
76. Calabro, M.L., Tommasini, S., Donato, P., Raneri, D., Stancanelli, R., Ficarra, P., Ficarra, R., Costa, C., Catania, S., Rustichelli, C., Gambrerini, G.: Effects of α- and β-cyclodextrin complexation on the physico-chemical properties and antioxidant activity of some 3-hydroxyflavones. J. Pharm. Biomed. Anal. 35, 365-377 (2004)
77. van Drooge, D.J.: Combining the incompatible; inulin glass dispersions for fast dissolution, stabilization and formulation of lipophilic drugs, Chap. 1 (introduction: production, stability, and dissolution of solid dispersions to improve the bioavailability of class II lipophilic drugs). PhD Thesis, Rijksuniversiteit Groningen (2006)